MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today anno...
This patent is expected to expire no earlier than June 2035. The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating sclero...
The approval of ELREXFIO (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study EL...
Company Activates Additional Study Location to Expedite Enrollment Completion HLHS is a congenital birth defect in which the left ventricle (one of the pu...
ImPact Biotech, a leader in photodynamic therapy, recently announced an agreement with Maastricht University to collaborate in research focused on eye...
Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broaden...
T-SCCC will support initiatives seeking to ensure success of organ transplants for patients The PPD clinical research business of Thermo Fisher Scientific...
The consistency evaluation of generic drugs evaluates approved generic drugs based on the principle that generic drugs need to reach the same level of qual...
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the...
QIAGEN announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit). This companion diagn...
Agilent Technologies Inc. (NYSE: A) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia...
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic enginee...
ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administrat...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
© 2024 Biopharma Boardroom. All Rights Reserved.
